CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 396 enrolled
Drug / intervention
Enzalutamide +1 moredrug
Likely dose
Enzalutamide 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01664923
NCT01664923Phase 2Completed
CompareCT.gov

STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY

Pfizer·interventional·Posted Aug 14, 2012·Updated Jan 30, 2019

In Brief

A Phase 2 clinical trial evaluating Enzalutamide and Bicalutamide for Prostate Cancer. Completed, enrolled 396 participants across 109 sites.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen deprivation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsAstellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 14, 2012
Enrollment StartAug 1, 2012
Primary CompletionFeb 1, 2015
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.9 years ago

Interventions

Enzalutamidedrug

160 mg, daily, by mouth.

Bicalutamidedrug

50 mg, daily, by mouth